Item 2.02. Results of Operations and Financial Condition

On January 9, 2023 ImmuCell Corporation (the "Company") issued a press release announcing the preliminary, unaudited product sales for the year ended December 31, 2022. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.




Item 9.01.  Financial Statements and Exhibits.



(d) Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:





99.1        Press Release of ImmuCell Corporation dated January 9, 2023.
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       1

© Edgar Online, source Glimpses